Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15190370 | 0.84 | SCD (0.51) | SCD | |
| SCHEMBL12836765 | 0.84 | SCD (0.51) | SCD | |
| SCHEMBL993242 | 0.83 | SCD (0.64) | SCD | |
| SCHEMBL1378991 | 0.82 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL1600528 | 0.82 | SCD (0.71) | SCDDCTPP1 | |
| SCHEMBL1379639 | 0.81 | SCD (0.85) | SCDDCTPP1 | |
| SCHEMBL1817135 | 0.81 | SCD (0.68) | SCD | |
| SCHEMBL1817527 | 0.81 | SCD (0.70) | SCDDCTPP1 | |
| SCHEMBL1379336 | 0.81 | SCD (0.75) | SCDDCTPP1 | |
| SCHEMBL995031 | 0.81 | HSD11B1 (0.59) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026360-B2 | Substituted pyridazines as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2011-09-27 | — | — | US | claimed |
| EP-2269610-A2 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2011-01-05 | — | — | EP | claimed |
| US-9358250-B2 | Methods of using SCD1 antagonists | GENENTECH, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| EP-1804799-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | disclosed |
| US-8026360-B2 | Substituted pyridazines as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| US-8026360-B2 | Substituted pyridazines as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| US-8026360-B2 | Substituted pyridazines as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| EP-2269610-A2 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269610-A2 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2011-01-05 | — | — | EP | disclosed |
| US-20090306090-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-12-10 | — | — | US | disclosed |
| US-20090306090-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-12-10 | — | — | US | disclosed |
| US-7592343-B2 | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2009-09-22 | — | — | US | disclosed |
| US-7592343-B2 | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2009-09-22 | — | — | US | disclosed |
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | US | disclosed |
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | SCD, SCD5, NR1H2 | SCD 1/4885DCTPP1 4259/4885 |
| US-20090306090-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, FADS2 | SCD 1/4885DCTPP1 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.